Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
O43865

UPID:
SAHH2_HUMAN

ALTERNATIVE NAMES:
DC-expressed AHCY-like molecule; IP(3)Rs binding protein released with IP(3); Putative adenosylhomocysteinase 2; S-adenosyl-L-homocysteine hydrolase 2

ALTERNATIVE UPACC:
O43865; B4E168; Q2TAJ6; Q502W8; Q5VSM0; Q6P171; Q96PK4; Q9UG84

BACKGROUND:
The multifunctional S-adenosylhomocysteine hydrolase-like protein 1, known for its regulatory roles in fluid secretion, mRNA processing, and cell cycle progression, is a key player in cellular homeostasis. By modulating the activity of ITPR1 and influencing Ca(2+) dynamics between the ER and mitochondria, AHCYL1 is crucial for both normal cellular operations and apoptosis under stress conditions.

THERAPEUTIC SIGNIFICANCE:
Exploring the multifaceted functions of S-adenosylhomocysteine hydrolase-like protein 1 offers a promising avenue for the development of novel therapeutic approaches. Its central role in managing cellular stress responses and maintaining homeostasis presents it as an attractive target for drug discovery in conditions marked by cellular dysfunction.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.